Stay updated with breaking news from Hc Wainwright. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) had its price target increased by HC Wainwright from $13.00 to $14.00 in a report released on Tuesday, Benzinga reports. They currently have a buy rating on the stock. Separately, Needham & Company LLC reiterated a buy rating and issued a $8.00 price objective on shares of Verrica Pharmaceuticals […]
HC Wainwright reaffirmed their neutral rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright also issued estimates for Aadi Bioscience’s Q2 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.73) EPS, Q1 2025 earnings at ($0.73) […]
HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a report released on Friday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock. Separately, Piper Sandler reaffirmed an overweight rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN […]
GlycoMimetics (NASDAQ:GLYC – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. Several other equities analysts also recently issued reports on GLYC. StockNews.com downgraded shares of GlycoMimetics from a “hold” rating to a “sell” rating in […]
GlycoMimetics (NASDAQ:GLYC – Get Free Report)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. Several other research analysts also recently issued reports on the stock. StockNews.com downgraded shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research report […]